Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, ...

Importantly, efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals. This safety and mature OS data build on the encouraging high overall response rate with ...